Academic Journal
Q1JACC: Heart Failure
About JACC: Heart Failure
JACC: Heart Failure is a scholarly journal published by Elsevier Inc.. SCImago 2025 places it in Q1 with an SJR of 4.036 and an H-index of 126.
Its listed coverage is 2013-2026 and its research categories include Cardiology and Cardiovascular Medicine (Q1). The 2025 dataset reports 369 documents and 3790 citations across the latest three-year reporting window.
JACC: Heart Failure – Advancing Research and Innovation in Heart Failure Care
JACC: Heart Failure is a premier peer-reviewed medical journal dedicated exclusively to the study and management of heart failure. Published by the American College of Cardiology (ACC), the journal serves as a vital resource for clinicians, researchers, and healthcare professionals focused on improving the lives of patients suffering from heart failure, one of the leading causes of hospitalization and mortality worldwide.
What is JACC: Heart Failure?
Launched as part of the Journal of the American College of Cardiology (JACC) family, JACC: Heart Failure delivers cutting-edge research, clinical insights, and evidence-based practices related to all aspects of heart failure. From novel therapeutic strategies to diagnostic tools and patient-centered care models, the journal covers a wide range of topics that reflect the evolving landscape of cardiology.
With a strong emphasis on both clinical and translational research, JACC: Heart Failure publishes original investigations, comprehensive reviews, editorials, and case reports that help bridge the gap between scientific discovery and clinical application. The journal’s content is rigorously peer-reviewed and curated by leading experts in the field.
Why JACC: Heart Failure Matters
Heart failure is a complex syndrome that affects millions globally and poses significant challenges to patients and healthcare systems alike. As new therapies and technologies emerge, clinicians need access to reliable, up-to-date information to guide treatment decisions and improve patient outcomes. JACC: Heart Failure addresses this need by providing high-quality, evidence-based content that reflects the latest scientific advancements.
The journal’s impact factor and growing readership make it a trusted source within the cardiovascular community. It plays a key role in shaping clinical guidelines and informing policy decisions related to heart failure care.
Topics Covered by JACC: Heart Failure
JACC: Heart Failure features research and clinical studies on a wide array of heart failure-related topics, including:
-
Acute and chronic heart failure management
-
Advanced heart failure therapies, including mechanical circulatory support and transplantation
-
Pharmacological and device-based treatments
-
Biomarkers and imaging techniques
-
Patient quality of life and outcomes
-
Health disparities and global perspectives on heart failure
-
Preventive strategies and risk reduction
-
Precision medicine and personalized care approaches
This wide-ranging scope ensures that the journal remains at the forefront of cardiology research and is highly relevant to healthcare professionals worldwide.
Accessing JACC: Heart Failure
JACC: Heart Failure is available both online and in print. Subscribers can access full-text articles through the JACC.org platform, which also offers search tools, article collections, and multimedia content like podcasts and expert interviews. Many articles are open access, ensuring that critical information is readily available to the broader medical community.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Scope of JACC: Heart Failure – Advancing Research in Cardiovascular Care
JACC: Heart Failure is a premier peer-reviewed journal under the umbrella of the Journal of the American College of Cardiology (JACC). As a dedicated platform for the latest developments in heart failure, the journal serves as a critical resource for clinicians, researchers, and healthcare professionals worldwide. Its scope encompasses all aspects of heart failure, from pathophysiology and diagnosis to innovative therapies and clinical outcomes.
Focused on Comprehensive Heart Failure Research
The primary scope of JACC: Heart Failure includes high-quality original research that advances the understanding and treatment of heart failure. The journal covers a broad range of topics, such as:
-
Epidemiology and Risk Stratification
Studies analyzing the prevalence, incidence, and risk factors associated with heart failure, aiming to enhance early detection and prevention. -
Basic and Translational Science
Groundbreaking research that uncovers the molecular and cellular mechanisms of heart failure, facilitating the development of targeted therapies. -
Clinical Trials and Therapeutic Strategies
Reports on randomized clinical trials, observational studies, and real-world data that evaluate pharmacologic and device-based interventions. -
Advanced Heart Failure and Transplantation
Research addressing mechanical circulatory support, heart transplantation, and end-of-life care in patients with advanced heart failure. -
Imaging and Diagnostics
Innovations in cardiac imaging, biomarkers, and diagnostic tools that support early and accurate diagnosis.
Promoting Global Impact and Clinical Relevance
JACC: Heart Failure emphasizes clinical applicability and global relevance. The journal encourages submissions that address disparities in care, global health trends, and emerging challenges in the management of heart failure across diverse populations.
It also highlights state-of-the-art reviews, editorials, and clinical perspectives that synthesize current knowledge and guide best practices in heart failure care.
Interdisciplinary and Collaborative
The scope of the journal fosters collaboration across disciplines, bridging the gap between cardiology, internal medicine, surgery, pharmacology, and public health. With a commitment to publishing timely and impactful research, JACC: Heart Failure supports innovation and evidence-based care models to improve patient outcomes.
Why Publish in JACC: Heart Failure?
-
High Visibility and Impact Factor
The journal boasts a high impact factor, ensuring that research published within it reaches a wide audience and garners significant citations. -
Rigorous Peer Review
Each submission undergoes a meticulous review process by leading experts in the field, ensuring scientific integrity and clinical relevance. -
Global Readership
As part of the JACC family, the journal reaches cardiologists, healthcare providers, and researchers across the globe.
Recent Research Articles
Latest publications matched automatically by ISSN.
Defining Clinically Meaningful Within-Patient Changes in Heart Failure
Amin Yehya, Rebecca Hahn, Barry Borlaug, Victoria Delgado et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103310Residual Inflammatory Risk of Heart Failure and Atherosclerotic CVD in Diabetes
Kershaw V. Patel, Leonard Chiu, Katelyn R. Garcia, L. Maria Belalcazar et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103296Frailty Patterns, Reversibility, and Outcomes With a Magnetically Levitated Left Ventricular Assist Device
Nelson Wang, Ameesh Isath, Ivan Netuka, Ulrich Jorde et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103313Effect of Omecamtiv Mecarbil According to PREDICT-HF Risk Score
Misato Chimura, Kirsty McDowell, Pardeep S. Jhund, Kieran F. Docherty et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103302Genetic, Preclinical, and Clinical Evidence Supports SGK1 Inhibition in Heart Failure
Sabindra Pradhananga, Dinesh Srinivasan, Eric Campeau, Marc Vidal et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103304The MagMa Study
Phillip Suwalski, Finn Wilke, Ekaterina Latinova, Gabriele Paci et al.
2026-08 · DOI: 10.1016/j.jchf.2026.103182Contemporary Trends in Heart Failure Mortality
Eiran Z. Gorodeski, Shashank Shekhar, Robert A. Montgomery, Biykem Bozkurt et al.
2026-08 · DOI: 10.1016/j.jchf.2026.103066Prognostic Significance of Low Alanine Aminotransferase in Transthyretin Amyloid Cardiomyopathy
Chern Hsiang Choy, Tunde Ogunsakin, Shanat Baig, Guy Pratt et al.
2026-08 · DOI: 10.1016/j.jchf.2026.103290Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure
Christiane E. Angermann, Teresa Gerhardt, Jonathan P. Blatchford, Jan Biegus et al.
2026-08 · DOI: 10.1016/j.jchf.2026.102999Cost-Effectiveness of Tirzepatide for the Management of Heart Failure With Preserved Ejection Fraction and Obesity
Tadesse M. Abegaz, Gabriel Frietze, Akshaya Srikanth Bhagavathula, Askal Ayalew Ali et al.
2026-08 · DOI: 10.1016/j.jchf.2026.103060Myocardial Histopathology-Based Heart Failure Phenotyping
Gregorio Tersalvi, Joseph J. Maleszewski, Surendra Dasari, Sammy Arab et al.
2026-08 · DOI: 10.1016/j.jchf.2026.103369Cardiac function and the effect of heart failure treatment in patients with genotype-positive dilated cardiomyopathy
Paul Anders Sletten Olsen, Ida Skrinde Leren, Øyvind Haugen Lie, Cecilie Bugge et al.
2026-08 · DOI: 10.1016/j.jchf.2026.103367Genetically Proxied Interleukin-6 Signaling Inhibition and Heart Failure Risk
Panagiotis Zangas, Art Schuermans, Marios K. Georgakis
2026-08 · DOI: 10.1016/j.jchf.2026.103057Forty Years of Heart Failure Drug Clinical Trials
Andrea D. Rivera, Mitchell A. Psotka, Mona Fiuzat, Christopher M. O’Connor et al.
2026-08 · DOI: 10.1016/j.jchf.2026.103068Refining the Definition for “Low Risk” in Pulmonary Arterial Hypertension
Charles Fauvel, Priscilla Correa Jaque, Yongqi Liu, Sang Wan Lee et al.
2026-08 · DOI: 10.1016/j.jchf.2026.103151Dapagliflozin in Patients With Heart Failure Across the Care Spectrum
David D. Berg, Muthiah Vaduganathan, Kieran F. Docherty, Andrea Bellavia et al.
2026-08 · DOI: 10.1016/j.jchf.2026.103232Payer-Driven Disparities in Cardiogenic Shock
Nava Raj Sharma, Saral Lamichhane, Prasun Khanal, Ilya Giverts et al.
2026-08 · DOI: 10.1016/j.jchf.2026.103307Fetal Right Ventricular Dilatation and Dysfunction as a Precursor of Dilated Cardiomyopathy
Francesca Bonanni, Adalgisa Cordisco, Giovanni Battista Calabri, Francesca Girolami et al.
2026-08 · DOI: 10.1016/j.jchf.2026.103048Editorial Board
2026-08 · DOI: 10.1016/s2213-1779(26)00345-8Enabling a Renin-Angiotensin System Inhibitor and/or a Mineralocorticoid Receptor Antagonist in Patients With Heart Failure and/or Chronic Kidney Disease
Bertram Pitt, Javed Butler, Matthew R. Weir
2026-08 · DOI: 10.1016/j.jchf.2026.103114Reviews
Community Reviews
Version History
April 20, 2025 at 9:07 am
April 20, 2025